文献速递炎症性肠病

糖皮质激素联合美沙拉秦对比单用糖皮质激素治疗急性重度溃疡性结肠炎:一项随机对照试验

Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-03-08

这项随机对照、研究者盲法试验在7个国家10个中心纳入149例急性重度溃疡性结肠炎住院患者,比较糖皮质激素联合美沙拉秦(4 g/天)与单用糖皮质激素的疗效。第7天缓解率联合组为72.6%(53/73),单用组为76.3%(58/76),差异无统计学意义(OR 0.82,95%CI 0.39-1.72,P=0.60)。联合组第30天和第90天生物制剂需求在数值上较低,但差异未达统计学显著。

要点

  • 联合美沙拉秦并未提高第7天缓解率:72.6% vs 76.3%(OR 0.82,95%CI 0.39-1.72,P=0.60)。
  • 住院时长、C反应蛋白正常化率及90天内结肠切除率两组无差异。
  • 联合组第30天(P=0.11)和第90天(P=0.07)生物制剂需求在数值上较低,但未达统计学显著。

核心结论

  • 在急性重度溃疡性结肠炎住院患者中,糖皮质激素联合美沙拉秦较单用糖皮质激素并未带来更多获益。
  • 美沙拉秦组第90天生物制剂需求减少的探索性信号值得进一步评估。

研究设计与样本

  • 随机对照、研究者盲法临床试验,在7个国家10个中心开展。
  • 筛选346例,纳入149例(女性70/149;中位年龄41岁);联合组73例,单用组76例。
  • 按入院前美沙拉秦使用情况分层随机;美沙拉秦剂量为4 g/天。
  • 纳入标准为急性重度溃疡性结肠炎住院患者(Lichtiger评分≥10)。

主要发现

  • 主要结局第7天缓解率:联合组53/73(72.6%)vs 单用组58/76(76.3%)(OR 0.82,95%CI 0.39-1.72,P=0.60)。
  • 两组住院时长、C反应蛋白正常化率及第90天结肠切除率均无差异。
  • 联合组第30天(P=0.11)和第90天(P=0.07)生物制剂需求在数值上低于单用组,但未达统计学显著。
  • 缓解定义为Lichtiger评分下降>3分且绝对评分<10,无需挽救治疗或结肠切除。

局限性

  • 原文未报告局限性;作者在结论中指出美沙拉秦组第90天生物制剂需求减少为探索性信号,值得进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Corticosteroids are the mainstay of treatment for hospitalized patients with acute severe ulcerative colitis (ASUC). However, whether the addition/continuation of mesalamine with corticosteroids during hospitalization is superior to corticosteroids alone is unknown. METHODS: This was a randomized controlled, investigator-blinded, clinical trial conducted in 10 centers in 7 countries. Patients hospitalized with ASUC (Lichtiger score ≥10) were eligible. Patients received corticosteroids alone or corticosteroid + mesalamine (4 g/day mesalamine) by a stratified randomization according to mesalamine use before admission. The primary outcome was the percentage of patients who responded to treatment by day 7, defined by a drop >3 points in the Lichtiger score and an absolute score <10 without the need for rescue medications or colectomy. RESULTS: Three hundred forty-six patients were screened, and 149 were included (70/149 female; median age, 41 years). Of these, 73 received corticosteroids + mesalamine, and 76 received corticosteroids alone. For the primary outcome, 53 of 73 patients (72.6%) receiving corticosteroids with mesalamine responded versus 58 of 76 patients (76.3%) on corticosteroids alone (odds ratio, 0.82; 95% confidence interval, 0.39-1.72; P = .60). There was no difference between groups in duration of hospitalization, C-reactive protein normalization rate, or colectomy rate up to day 90. The need for biologics among patients receiving combination of corticosteroids with mesalamine was numerically lower by day 30 (P = .11) and day 90 (P = .07). CONCLUSIONS: In this randomized controlled trial, combination of mesalamine with corticosteroids did not benefit hospitalized patients with ASUC more than corticosteroids alone. An exploratory signal for a reduced need for biologics at 90 days in the mesalamine group merits further evaluation. CLINICALTRIALS: gov ID: NCT01941589.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ben-Horin S, Har-Noy O, Katsanos KH, et al. Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2022. PMID: 35272029. doi:10.1016/j.cgh.2022.02.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。